<DOC>
	<DOCNO>NCT00807599</DOCNO>
	<brief_summary>The purpose study compare effect , good bad , two way treat patient standard-risk symptomatic multiple myeloma . Patients standard-risk myeloma myeloma specific feature : level 2 blood test specific range myeloma tumor find outside bone bone marrow , area myeloma usually discover . In past clinical study , patient standard-risk myeloma do well intensive therapy form stem cell transplant . But multiple myeloma curable , although may respond standard treatment include stem cell transplant , myeloma always recur .</brief_summary>
	<brief_title>Lenalidomide ( Revlimid® ) Plus Low-dose Dexamethasone ( Ld x 4 Cycles ) Then Stem Cell Collection Followed Randomization Continued Ld Stem Cell Transplantation ( SCT ) Plus Maintenance L</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age ≥ 18 ≤ 75 Histologic serologic finding MSKCC confirm diagnosis multiple myeloma . Standard diagnostic criterion multiple myeloma use , per revise International Myeloma Working Group diagnostic criterion . Patients must symptomatic multiple myeloma without advanced organ damage ( multiple fracture advance bone disease cause immobilization , renal failure , spinal cord compression , organ compromise due soft tissue plasmacytoma ) . If immediate therapy radiation highdose steroid ( eg , cord compression ) bortezomibbased therapy ( eg , renal failure ) require , patient eligible trial . Patients may receive 1 cycle prior therapy dexamethasone multiple myeloma . Adequate organ function require , defined follow : ANC ≥ 1,500/μl platelet ≥ 100,000/μl ( unless low ANC platelet due multiple myeloma ) Serum bilirubin ≤ 2.0 mg/dl AST , ALT alkaline phosphatase &lt; 3 time upper limit laboratory normal Adequate renal function assess calculated creatinine use CockcroftGault estimation CrCl ( see Appendix I ) : Subjects must calculate creatinine clearance ≥ 30ml/min CockcroftGault formula Performance status ( ECOG ) ≤ 2 ( Appendix E ) . Eligible SCT LVEF ≥ 50 % MUGA ECHO , diffuse capacity &gt; 50 % predict pulmonary function test Ability understand investigational nature study give inform consent All study participant must register mandatory Revlimid REMS® program , willing able comply requirement Revlimid REMS® program Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prior prescribe lenalidomide cycle 1 ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree father child agree use latex condom sexual contact female child bear potential even successful vasectomy . See Appendix C : Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods . Able take aspirin 325mg 81mg daily prophylactic anticoagulation ( patient intolerant ASA may use Coumadin low molecular weight heparin ) . Prior treatment myeloma except one cycle dexamethasone History thromboembolic disease within past 6 month regardless anticoagulation Myocardial infarction within 6 month prior enrollment , New York Hospital Association ( NYHA ) Class III IV heart failure ( see APPENDIX F ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Pregnant breastfeed woman exclude due potential teratogenicity lenalidomide . Concurrent active malignancy nonmelanoma skin cancer carcinomainsitu cervix , presence myelodysplastic myeloproliferative disease . Patients prior malignancy diseasefree interval ≥ 5 year eligible . Patients prior malignancy within past 5 year consider `` cured '' low likelihood recurrence may eligible discretion Principal Investigator . Active hepatitis B C infection HIV 1 2 positivity Any medical condition laboratory evaluation , treat physician 's principal investigator 's opinion , make patient unsuitable participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CYCLOPHOSPHAMIDE ( CYTOXAN )</keyword>
	<keyword>DEXAMETHASONE</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>MELPHALAN</keyword>
	<keyword>PEG-FILGRASTIM ( NEULASTA )</keyword>
	<keyword>08-121</keyword>
</DOC>